Competing risks data often exist within a center in multi-center randomized clinical trials where the treatment effects or baseline risks may vary among centers. In this paper, we propose a subdistribution hazard regression model with multivariate frailty to investigate heterogeneity in treatment effects among centers from multi-center clinical trials. For inference, we develop a hierarchical likelihood (or hlikelihood) method, which obviates the need for an intractable integration over the frailty terms. We show that the profile likelihood function derived from the h-likelihood is identical to the partial likelihood, and hence it can be extended to the weighted partial likelihood for the subdistribution hazard frailty models. The proposed method is illustrated with a dataset from a multi-center clinical trial on breast cancer as well as with a simulation study. We also demonstrate how to present heterogeneity in treatment effects among centers by using a confidence interval for the frailty for each individual center and how to perform a statistical test for such heterogeneity using a restricted h-likelihood.
Introduction
Competing risks (CR) data arise when an occurrence of an event precludes other type of events from being observed. 1 Two broad classes of models for analyzing the CR data have been developed based on Cox's proportional hazards (PH) models; one is to model the cause-specific hazard of the different event types 2 and the other is to model the subhazard (i.e., the hazard function of a subdistribution) for the event of interest. 3 In particular, the subhazard model by Fine and Gray, 3 often referred to as the Fine-Gray model, directly associates covariate effects with the cumulative probability of a specific cause of events over time, i.e., the cumulative incidence function (CIF), whereas the cause-specific hazard model associates the covariate effects with the cause-specific hazard function. Therefore, if one is interested in direct statistical inference on the cumulative probability of cause-specific events, Fine-Gray model would be more appropriate.
In this paper, we model the subhazard for the CR data from multi-center randomized clinical trials, which are often observed within a cluster (e.g., center). In many applications involving CR data, individual events within a cluster may be correlated due to unobserved shared factors across individuals. The Fine-Gray model, however, takes no account for such correlation, which can be modeled by the frailty (or random effect). 4, 5 Thus, Katsahian et al. 6 and Christian 7 have extended the Fine-Gray model to a subhazard frailty model with a random center effect only. It would be practically more useful to model heterogeneity in treatment effect among centers as well as the random center effect, where the two random effects might be correlated. 8, 9 Here, the heterogeneity in treatment effect among centers can be modeled as an additive frailty term to a regression coefficient for the baseline treatment effect without heterogeneity. 10 In this paper, we extend the standard correlated frailty modeling approach 5, [10] [11] [12] to a subhazard frailty modeling approach to handling the potential heterogeneity in treatment effect in CR data from multi-center clinical trials.
For inference, we develop a hierarchical likelihood (or h-likelihood; Lee and Nelder 13 ) method; it obviates integration itself over the frailty distributions and also gives a statistically efficient estimation procedure for various random-effect models. 10, 13, 14 In particular, we show that the profile likelihood function derived from the h-likelihood is identical to the partial likelihood, and hence it can be extended to the weighted partial likelihood for the subdistribution hazard frailty models. The proposed method is illustrated with time-to-event data from a phase III breast cancer trials (B-14) conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP), which consist of 2817 patients from 167 centers, 15, 16 as well as a simulation study. We also demonstrate via the practical data set how to present heterogeneity in treatment effect among centers by using a confidence interval 17, 18 for the frailty for each individual center, not the parameters for the frailty distribution, and how to perform a statistical test for such heterogeneity using a restricted h-likelihood. 14 The paper is organized as follows. In the next section, we propose a formulation of subhazard frailty models. In Section 3, we show how the h-likelihood can be extended to the subhazard frailty models, and develop the h-likelihood estimation procedure for fitting the models. A simulation study is conducted to evaluate the performance of the proposed method in Section 4. The new method is illustrated using the breast cancer data set in Section 5. Finally, we discuss our method in Section 6. The technical derivations and additional simulation results are presented in Appendix 1 and Supplementary Material, respectively.
Formulation for subhazard frailty models
Suppose that the data consist of censored time-to-event observations collected from q centers (or clusters). We also assume that there are L distinct event types in each center. For subject j of center i, let T ij be the time to the first event and let ij 2 f1, 2, . . . , Lg be the corresponding cause of event 
For simplicity, in this paper we consider the two event types (L ¼ 1,2). Thus, ij 2 f0, 1, 2g; it is 1 for an event of interest, 2 for a competing event, and 0 for censoring.
Fine and Gray 3 first introduced a way to directly associate the effects of covariates with CIF, which models the subhazard for the event of interest, L ¼ 1. Furthermore, Katsahian et al. 6 and Christian 7 have extended Fine-Gray model to a subhazard frailty model with only one random component (i.e., random center effect) to analyze multi-center CR data.
In this paper, we show that, for the purpose of more systematic analysis, the model above needs to be extended to a general subhazard frailty model allowing multiple random components (e.g., random center and random treatment effect) and their correlation, as in Ha et al. 10 Here, random treatment effect means random treatment-by-center interaction. In particular, a model allowing for the correlation between random center and random treatment effects can properly account for the heterogeneities from the treatment effect across centers as well as between-center variation. 10 Denote
T an r-dimensional vector of unobserved log-frailties (random effects) associated with the ith ði ¼ 1, . . . , qÞ center. Note that in equation (1), u i ¼ expðv i Þ (i.e., v i ¼ log u i ) are referred to frailties. 5, 8, 10 As described in Fine and Gray 3 and Ha et al., 19 we assume that given v i , T ij , ij À Á , and C ij , j ¼ 1, . . . , n i , are conditionally independent, and that given v i , C ij , j ¼ 1, . . . , n i , are non-informative about v i . Suppose that we are interested in assessing the effects of covariates on the conditional CIF for cause 1 given the log-frailties v i , defined by 
is the linear predictor for the log-hazard, and x ij ¼ ðx ij1 , . . . , x ijp Þ T and z ij ¼ ðz ij1 , . . . , z ijr Þ T are p Â 1 and r Â 1 covariate vectors corresponding to fixed effects ¼ ð 1 , . . . , p Þ T and log-frailties v i , respectively. We assume that the log-frailties v i are independent and follow a multivariate normal distribution, v i $ N r ð0, AE i ðÞÞ, where the covariance matrix AE i ðÞ depends on a vector of unknown parameters . The normal distribution has been used for modeling multi-component 20 and correlated frailties. Model (1) includes some well-known models as special cases. In a multi-center medical study, let v i0 be a random intercept or random center effect that modifies the baseline risk for center i, and let v i1 be associated with the treatment effect, i.e., a random treatment effect (or random treatment-by-center interaction). In equation (1), if we consider z ij ¼ 1 and v i ¼ v i0 for all i, j, this becomes the random center or shared frailty model 6, 7 with
where v i0 $ Nð0, 2 0 Þ for all i. Model (2) can be extended as follows. Let 1 be the main treatment effect associated with the treatment indicator x ij1 and let m ðm ¼ 2, . . . , pÞ be the fixed effects corresponding to the covariates x ijm . Our two random components lead to a bivariate model 9, 10 with
which is easily derived by taking z ij ¼ ð1,
. Here, to maintain the invariance of model to parameterization of the treatment effect we allow a general covariance matrix 9, 14 between v i0 and v i1 within a cluster
where the correlation is denoted by ¼ 01 =ð 0 1 Þ. The bivariate normal (BN) model (3) with (4) is very useful for investigating heterogeneity in the baseline risk and the treatment effect across centers.
H-likelihood estimation
In this section, we show how to construct systematically the h-likelihood estimation procedure for fitting the semiparametric subhazard frailty model (1) . For this, we first show how to construct the h-likelihood, and then propose the estimation procedure. The general case for incomplete (censoring) data is presented here as in Pintilie 1 because the proposed method can be directly applied to complete (no censoring) data. 
H-likelihood construction
where
is the sum of the logarithm of the conditional density function for Y ij and ij given v i , i.e., the ordinary log-likelihood for censored survival data given
; y ij , ij jv i Þ, and
is the logarithm of the density function for v i with parameters ¼ ð 
Þ T , and d ðkÞ is the number of the events of interest at y ðkÞ . As the number of s 01k 's can increase with the number of distinct event times, the function s 01 ðtÞ is potentially of high dimension. Accordingly, for estimation of (,v) Ha et al. 19 proposed the use of the profiled h-likelihood h * from which
are solutions of the estimating equations, @h=@
with a constant term P k d ðkÞ flog d ðkÞ À 1g eliminated, so that h* becomes the penalized partial likelihood (PPL): 11, 23 see also Appendix C of Ha et al. 10 In particular, the first term,
of h* in equation (6) can be viewed as the log-partial likelihood for the Fine-Gray model given v i , by treating the observed event times y ij 's as complete outcomes.
In the case of right censoring under CR, Fine and Gray 3 developed a weighted score function based on the complete-data partial likelihood. Thus, the inverse probability of censoring weighting (IPCW) by Fine and Gray 3 can be equally applied to the first term of h* as in Pintilie 1,24 and Katsahian et al. 6 Accordingly, a weighted partial h-likelihood h Ã w based on the IPCW is defined by
Here is the weight of subject j of center i at y ðkÞ , andĜðÁÞ is the Kaplan-Meier estimate of the survival function for the censoring times. Here, w ij ¼ 1 as long as individuals have not failed (i.e., y ij ! y ðkÞ ; the first condition of R ðkÞ ), whereas w ij 1 and decreasing over time if they failed from Type 2 (i.e., y ij y ðkÞ and ij 6 ¼ 1; the second condition of R ðkÞ ). 1, 24 Note that h Ã w in equation (7) is an extension of the weighted log-partial likelihood 1, 24, 25 for the Fine-Gray model to the subhazard frailty models (1) . We can show that, under the subhazard shared model (2), h Ã w is also equivalent to the PPL of Katsahian et al., 6 by combining R ðkÞ and w ij as in equation (17) of Appendix 1.
Estimation procedure
Now, Ha et al.'s 10 procedures for standard correlated frailty models without CR can be extended to the subhazard model (1) by using h Ã w in equation (7). That is, given frailty parameters , the maximum h-likelihood (MHL) estimators of ¼ ð T , v T Þ T are obtained by solving the joint estimating equations, @h Ã w =@ ¼ 0. In Appendix 1, we show that given , the joint equations lead to Ha and Lee's 26 MHL estimator score equations for
where X and Z are n Â p and n Â q Ã model matrices for and v whose ijth row vectors are x T ij and z T ij , respectively, W* is the symmetric weight matrix given in equation (18) of Appendix 1, and
Note the s 01k terms in both W* and w* are evaluated at w 01k given in equation (16) (9) is an adjusted form for such elimination, 13, 14 leading to restricted maximum likelihood (REML) estimator for . The REML estimator for is obtained by solving iteratively
Note here that 3 proposed a robust/sandwich variance estimator to estimate varðÞ using an empirical process theory because the martingale properties break down under the FineGray model due to the use of IPCW and thus the standard asymptotic theories are no longer valid. Furthermore, in the subhazard frailty model (2) with one frailty term Katsahian and Boudreau 27 presented a robust variance estimator of using Gray's 28 method, estimated from
However, the proposed method, H À1 w , has been also used as a variance estimator in the context of the PPL: see Verweij and Van Houwelingen 29 and Therneau et al. 12 We investigate the performance of the two variances of by simulation studies in next section. Accordingly, the current estimation procedure can be implemented by replacing the risk indicator matrix in Ha et al.'s 10 procedure with a weighted risk indicator matrix (i.e., M in equation (17) of Appendix 1) which contains both the weights w and the risk set R used for modeling the subhazard function: see also Ruan and Gray. 30 Further, quantities (e.g., confidence intervals of frailties) are also directly applied.
In summary, the estimates of and are obtained by alternating between the two estimating equations (8) and (10) until convergence is achieved. 10, 26 At convergence, we compute the SEs of À and. Note that the h-likelihood procedure performs well under any restrictions for cluster size n i such as n i ¼ 1 and unbalanced cases. 10, 20, 31 The equation (8), which estimates all random effects simultaneously from the weighted h-likelihood in equation (7), may influence the consistency of fixed parameters (,), particularly for a small cluster size n i . However, here the resulting biases decrease quickly as n i rather than q increases: 26, 31 see also the simulation results of Section 4. Furthermore, when n i is very small, the biases can be further reduced using the Laplace approximation based on the h-likelihood: see Lee et al. 14 For a subhazard shared frailty model (2), the procedures proposed by Katsahian et al. 6 and Katsahian and Boudreau 27 are based on the PPL. 11, 23 Given frailty parameters , the PPL and hlikelihood methods provide the same estimates for and v. However, the two methods do not yield the same final results for and v because they give different estimators for . 10, 26 That is, the PPL method ignores the @v=@ term in solving the estimating equations of , given in equation (10); this leads to an underestimation of the parameters , particularly when the cluster size n i is small: see also simulation results by Ha and Lee 26 and Christian. 
Simulation study
Simulation study is conducted to evaluate the performance of the proposed method under the subhazard frailty models (3) with a general correlation structure (4) by using 1000 replications of simulated data. The simulated data are generated using a method similar to that of Fine and Gray 3 and Katsahian and Boudreau. 27 We consider two covariates x ij ¼ ðx ij1 , x ij2 Þ T and a BN random effect
T with mean 0 and covariance matrix having 
is the proportion of Type 1 events and
Here, 11 and 12 are regression parameters for Type 1 events. Thus, the conditional distribution function of T ij given a Type 1 event as well as x ij and v i is given by
Times to Type 1 event of interest are then generated from the distribution function above equation (12) using the probability integral transformation, conditional on x ij and v i . The conditional subdistribution for Type 2 events is simply obtained by taking 
, and 21 and 22 are regression parameters for Type 2 events. Thus, the conditional distribution function of T ij given a Type 2 event as well as x ij and v i is given by
As before, Type 2 event times (times-to-CR event) are generated from the distribution function equation (13) 27 we also consider the three sample sizes: n ¼ P q i¼1 n i with n ¼ 200, 400, and 1000, and (q,n i ) ¼ (20, 10) , (20, 20) , and (50, 20). The covariates x ij1 are generated from a Bernoulli random variable with probability 0.5 in order to mimic the binary treatment covariate of the multi-center study, and x ij2 are from a standard normal distribution. The covariance parameters of the random effects are Though not reported here, we found similar results for 01 ¼ 0.25. Censoring times are generated from a Uniform(a, b) distribution where the values of a and b were empirically selected to achieve the approximate right censoring rate, low (around 25%) and high (around 50%). That is, in Case A we used Uniform(1, 2.6) and Uniform(0.45, 1) for the censoring rates 25% and 50%, respectively, and in Case B we used Uniform(0.2, 1.7) and Uniform(0, 0.7) for the censoring rates 25% and 50%, respectively.
For the 1000 replications, we computed the mean, standard deviation (SD), and the mean of the estimated standard errors (denoted by SE1) for 1 1 , we calculated the mean of estimated standard errors (denoted by SE2) using a robust variance formula in equation (11) . All computations were done using SAS/IML. The simulation results are summarized in Table 1 .
Our method overall performs well even when the censoring rate is as high as 50%. In particular, the increase of n or n i , rather than q, reduces bias more effectively: see also Ha and Lee. 26 In Table 1 , the SD is the empirical estimates of fvarð 1j Þg 1=2 ð j ¼ 1, 2Þ, and SE1 and SE2 are the averages of the proposed and robust SE estimates for 1j , respectively. Our SE1ð 1j Þ work well as judged by the very good agreement between SE1 and SD. Similarly, our SE1s for also perform well. On the other hand, the SE2ð 11 Þ are seriously underestimated even if n increases, but the SE2ð 12 Þ work well. A possible reason is that the SE2 may be sensitive to the random-effect structures because 11 depends on the random treatment-by-center interaction (v i1 ) via the same covariates x ij1 , but 12 does not. The trends in Table 2 are similar to those evident in Table 1 . In particular, with a smaller sample as in n ¼ 200 the biases of frailty-parameter estimators are largely reduced, as compared to those in Table 1 .
In addition, we carried out the simulation studies of Cases A and B above under a subhazard shared frailty model (2) with ij ¼ v i0 þ 11 x ij1 þ 12 x ij2 and 2 0 . Here, for the censoring and covariate patterns, we follow the schemes of Katsahian and Boudreau. 27 Furthermore, the performances of likelihood ratio tests (LRT) based on the h-likelihood are evaluated for testing H 0 : Tables S1 and S2 in Supplementary Material): (i) The trends of the estimates of the fixed parametersð 1 , Þ are quite similar to those presented in Table 1 , except for the standard errors for 1 . We have found that the results of SE1 and SE2 for 1j ð j ¼ 1, 2Þ are about the same; here x ij1 depends on 11 , but not the random center effect v i0 . (ii) The LRT statistic under 2 0 ¼ 0 is somewhat conservative because the observed size (i.e., the observed rate of rejecting H 0 at the 5% level under 2 0 ¼ 0) is less than the nominal level 5% as shown in Katsahian and Boudreau, 27 but it becomes closer to the nominal level 5% with sample size n i or n, especially for the Case B. (iii) The power of all tests increases as 2 0 and/or n increase. These results indicate that the LRT statistic overall performs well under the shared model (2).
A practical example 5.1 The data
We re-examine the data from the B-14 randomized multi-center breast cancer trial conducted by the NSABP. 15, 16 The 2817 eligible patients from 167 distinct centers were followed up for about 20 years since randomization. The number of patients per center varied from 1 to 241, with a mean of 16.9 and median of eight. The patients were randomized to one of two treatment arms, tamoxifen (1413 patients), or placebo (1404 patients). The average age of patients was 55, and the average tumor size was about 2 cm. The aim of this analysis is to investigate the effect of treatment on local or regional recurrence. Here, we consider two event types. The first type is local or regional recurrence (Type 1), and the second type is a new primary cancer, distance recurrence, or death (Type 2); only the event that occurs firstly is of interest in this analysis, so that the repeated event times are not considered. Table 3 gives the number of first-observed event types in this data set; Type 1 is an event of interest (314 patients; 11.15%), Type 2 is an event of CR (1303 patients; 46.25%), and no-events until the last follow-up are censoring (1200 patients; 42.60%). Table 3 also shows the number of first-observed event types by two treatment arms. Figure 1 presents the estimated CIFs 1 for the two treatment arms. The tamoxifen group has lower CIFs compared to placebo group for both Type 1 and Type 2. For Type 1, the difference of CIFs of two arms seems to be large, whereas for Type 2 it does not. In particular, the estimated probability that a patient of tamoxifen group will experience Type 1 event within 10 years after surgery is 5%, while for a patient of placebo group it is 10%.
Analyses using subhazard models
For the data analysis, we consider the three covariates of interest: treatment (x ij1 is 1 for tamoxifen and 0 for placebo), age (x ij2 ), and tumor size (x ij3 ) as continuous covariates. Let, v i0 and v i1 be random center effects and random treatment effects (i.e., random treatment-by-center interaction), respectively. Following Ha et al., 10 we consider the three submodels of (1) for the time to Type 1 event, which include the proportional subhazards model without random effects (i.e., Fine-Gray model) and two subhazard frailty models. In other words, we consider the following three models, Table 4 .
In all the three subhazard models, the two fixed effects ð j , j ¼ 1, 2Þ are significant, except for 3 . In particular, the use of tamoxifen (tamoxifen ¼ 1) significantly reduces the risk of local or regional recurrence (Type 1 event) as compared to patients who receive placebo (placebo ¼ 0). We also observe that overall, there are no substantial changes in the fixed-effects estimates, although the effect of main treatment ( 1 ) becomes slightly weaker due to the increased standard error when the two random components and their correlation are included as in M3. In M2 and M3, the variance components ( 2 0 and 2 1 ) indicate the amount of variation between centers in baseline risk (i.e., center effect) and in the treatment effect, respectively. Here, the estimate and SE of 2 1 are relatively larger than those of 2 0 , which is also confirmed in Figure 2 . Furthermore, the correlated model M3 explains the degree of dependency between the two random components (i.e., the random center effect v 0 and the random treatment-by-center interaction v 1 ). The estimate of ( ¼ À0:721) gives a negative value, indicating that the two predicted random components (v 0 andv 1 ) have a negative correlation. In particular, the estimate of 1 in M3 is negative; we see that a decreasing value of v i1 corresponds to a larger treatment effect. Thus, the negative correlation leads to the conclusion that treatment confers more benefit in centers with a higher baseline risk. This is consistent with the findings by Rondeau et al. 9 in the context of meta-analysis and by Ha et al. 10 in that of multi-center trials.
Investigating and testing for heterogeneity
We demonstrate how to investigate heterogeneity related to treatment effect over centers using confidence intervals 17, 18 for frailties of the individual centers. Note that the standard intervals using p ðh Ã w Þ in equation (9) can be null due to zero estimation of the variance components, especially for small sample sizes or small variance components. 18, 33, 34 Thus, we follow Ha et al.'s 18 modification of equation (9) to deal with such shrinkage issue 12 for frailty. That is, for estimation of frailty parameters we use a further adjusted likelihood, defined by
which leads to non-negative variance-component estimators. Following Ha et al. 18 and equation (14) , the individual ð1 À Þ-level h-likelihood confidence intervals for the unidimensional components v k of random effects v are of the form wherev maximizes the profile h-likelihood h Ã w in equation (7), z =2 is the normal quantile with probability /2 in the right tail, and SEðv k À v k Þ are obtained from Hðh Ã w ;,vÞ À1 . In particular, Ha et al. 18 have shown via numerical studies that in a general class of frailty models without CR, the adjusted h-likelihood interval equation (15) preserves well the nominal interval. Figure 2 shows the estimates and 95% confidence intervals 17, 18 for the random effects in the 167 centers using the subhazard correlated model M3. Here, centers are ordered by the number of patients entered. Figure 2(a) and (b) gives the confidence intervals for the random center effect ðv i0 Þ and the random treatment-by-center interaction ðv i1 Þ, respectively. Overall, the lengths of the intervals are seen to decrease as the number of patients per center increases: see also Vaida and Xu 8 and Ha et al. 10 Figure 2(a) indicates overall homogeneity in the baseline risk across 167 centers (i.e., no variation in random center effect). Figure 2 (b) also shows there is no substantial variation in the effect of treatment across centers although three centers (148, 164, and 165) among 167 centers noticeably stand out. Note here that the centers (148, 165) and 164 provide the lowest and the highest treatment-by-center interactions, respectively, but that the corresponding three intervals include zero; this indicates there is little treatment-by-center interaction in this data set. Thus, in this multi-center trial there is little variation in the treatment effects across centers and the treatment is shown to be effective. These results suggest that the treatment effect may be generalized to a broader patient population as in the findings by Yamaguchi and Ohashi 35 and Ha et al. 10 Now, we show this heterogeneity can also be tested via the restricted h-likelihood in equation (9) . Recently, Katsahian and Boudreau 27 proposed how to test such heterogeneity (i.e., variation in random center effect) using the PPL method under the subhazard model (M2) with random center effect only. However, the heterogeneities from random treatment-by center interaction as well as random center effect should be simultaneously tested. For this purpose, we again consider the three models in Section 5.2. Note that although we report the SEs of the 2 s in Table 4 , one should not use them for testing H 0 : Table 4 , we obtain the deviance difference between M1 and M2 to be 1.1 (p ¼ 0.147), indicating that the random center effect is not significant (i.e., 
Discussion
We have shown that the proposed correlated frailty modeling approach based on the h-likelihood provides systematically more informative results for multi-center CR data. We have also demonstrated via a practical example how to investigate the heterogeneity related to treatment effect over centers and how to test such heterogeneity.
Our h-likelihood procedure can be also applied for fitting the cause-specific PH frailty models, 7, 38 by using the risk set in the classical Cox model. It would be an interesting comprehensive analysis to compare the inference results from both the subhazard and cause-specific frailty models for the Type 1 event in the breast cancer dataset presented in Section 5. We have shown via a simulation study that the LR tests based on the h-likelihood perform well under the subhazard shared frailty model (2) with one frailty parameter only. However, a simulation study under the subhazard frailty model (3) with a general correlation structure (4) might be challenging due to the number of parameters to be dealt with, and hence it would be an interesting future work. Another further work is to investigate the performance of the proposed method via a simulation study when the cluster size n i is random or data-directed unbalanced case 10 because in current simulation settings, n i is always fixed and at least 10.
The subhazard frailty models (1) implicitly assume that the frailty effects for the event of interest are independent of those for the other types of events (i.e., competing events). Developing an extended frailty modeling approach to allow a correlation between both events would be an interesting topic for future work.
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